FDA inspects wrong Chinese plant

The linkurl:US Food and Drug Administration;http://www.the-scientist.com/article/display/36885/ admitted yesterday that it never inspected a Chinese facility supplying the active ingredient in heparin, a widely used blood thinner recently implicated in more than 350 adverse reactions and four deaths in US patients. The oversight resulted from a case of mistaken identity, according to a linkurl:story;http://www.washingtonpost.com/wp-dyn/content/article/2008/02/18/AR2008021802315.html?wpisrc=newsl

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
The linkurl:US Food and Drug Administration;http://www.the-scientist.com/article/display/36885/ admitted yesterday that it never inspected a Chinese facility supplying the active ingredient in heparin, a widely used blood thinner recently implicated in more than 350 adverse reactions and four deaths in US patients. The oversight resulted from a case of mistaken identity, according to a linkurl:story;http://www.washingtonpost.com/wp-dyn/content/article/2008/02/18/AR2008021802315.html?wpisrc=newsletter in today's (Feb. 19) __Washington Post__. The FDA apparently inspected a similarly named Chinese company that had nothing to do with producing heparin or the drug's active ingredient, a compound derived from an enzyme in pig intestines. "To date this is an isolated situation, but the wrong firm was put into the database," Joseph Famulare, deputy director for compliance at the FDA's center for drug evaluation and research, told __The Post__. The FDA said that it is dispatching inspectors to China to determine if recent problems with the drug are a result of the agency's mistake. Two US companies, Baxter and APP Pharmaceuticals, distribute heparin in this country, but the reported problems have only involved Baxter's product, which sources its active ingredient from the un-inspected plant west of Shanghai.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
December digest cover image of a wooden sculpture comprised of multiple wooden neurons that form a seahorse.
December 2025, Issue 1

Wooden Neurons: An Artistic Vision of the Brain

A neurobiologist, who loves the morphology of cells, turns these shapes into works of art made from wood.

View this Issue
Stacks of cell culture dishes, plates, and flasks with pink cell culture medium on a white background.

Driving Innovation with Cell Culture Essentials

Merck
Stacks of cell culture dishes, plates, and flasks with pink cell culture medium on a white background.

Driving Innovation with Cell Culture Essentials

MilliporeSigma purple logo
Abstract wireframe sphere with colorful dots and connecting lines representing the complex cellular and molecular interactions within the tumor microenvironment.

Exploring the Inflammatory Tumor Microenvironment 

Cellecta logo
An image of a DNA sequencing spectrum with a radial blur filter applied.

A Comprehensive Guide to Next-Generation Sequencing

Integra Logo

Products

brandtech logo

BRANDTECH® Scientific Announces Strategic Partnership with Copia Scientific to Strengthen Sales and Service of the BRAND® Liquid Handling Station (LHS) 

Top Innovations 2026 Contest Image

Enter Our 2026 Top Innovations Contest

Biotium Logo

Biotium Expands Tyramide Signal Amplification Portfolio with Brighter and More Stable Dyes for Enhanced Spatial Imaging

Labvantage Logo

LabVantage Solutions Awarded $22.3 Million U.S Customs and Border Protection Contract to Deliver Next-Generation Forensic LIMS